Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

NCT02489903 is registered in ClinicalTrials.gov with EpicentRx, Inc. as lead sponsor.

NCT NCT02489903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02489903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Lead sponsor
EpicentRx, Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2015
Completion date
December 6, 2021
Enrollment
139 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, neuroendocrine tumors, ovarian epithelial cancer, small cell carcinoma